HIV/AIDS News Alert!

FDA Updates STRIBILD and TYBOST labels
May 4, 2017 The STRIBILD and TYBOST labels were updated to include revised text regarding corticosteroids as follows:

STRIBILD
Section 7 Drug Interaction, Table 6 was revised for systemic, inhaled, nasal, and opthalmic corticosteroids as follows.

Table 6 Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction

Beclomethasone and Prednisolone were added to section 7.6 Drugs Without Clinically Significant Interactions with STRIBILD

TYBOST
Section 7 Drug Interaction, Table 6 was revised for systemic, inhaled, nasal, and opthalmic corticosteroids as follows. Additionally section 7.4 was added as shown below

Table 6 Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction

7.4 Drugs without Clinically Significant Interactions with TYBOST

No clinically significant drug interactions have been either observed or are expected when TYBOST is combined with the following drugs: beclomethasone and prednisolone

The updated labels will soon be available drugs@fda or DailyMed